Investors
Our start-up and equity portfolio secures funding from investors around the world who believe in our world-class science and the power of partnership.
We offer investment opportunities in new therapeutics, diagnostics, medical devices and data-driven and AI solutions.
79
start-ups formed to date
23
exits to date
£3bn
raised by our portfolio to date
What we offer
| Seed investment | Start-up support | Scientific expertise | Global network |
| Our Seed Fund has provided early-stage funding to 22 exciting new ventures so far, and our portfolio continues to grow with several ground breaking opportunities in stealth. | Our expert teams guide researchers in developing their promising discoveries - from entrepreneurial training, advice and funding through to seed investment and commercial support for company formation and scaling up. | We leverage our drug discovery and development expertise in partnerships with researchers and industry to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines. | We have unparalleled access to a global network of researchers, clinicians and partners allowing us to call on world-leading experts to validate translational potential and inform our investment decisions. |
iOnctura's €80m in Series B financing
Investor news
"iOnctura represents a compelling opportunity to invest in line with our strategy and capital allocation focus in a clinical-stage company"
-Roel Bulthuis, Managing Partner and Head of Investments at Syncona and Board member of iOnctura
Our start-up portfolio
We've built an incredible assembly line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit.
To date, we've played a role in the creation of 79 start-ups, with our portfolio of existing companies raising in excess of £3bn in total capital.
Ventures team
Our Ventures team have a long-standing track record of sourcing, evaluating and creating start-ups. They manage the Seed Fund work alongside an independent investment committee to review applications.
Myricx Bio’s £90m Series A financing to advance ADCs to the clinic
Investor news
“We’ve been strong supporters of Myricx Bio since its inception, recognising the potential of its NMT inhibition platform. We are delighted to be joined by Abingworth, Novo Holdings, Lilly, Cancer Research Horizons and British Patient Capital as we continue to champion Myricx’s ability to harness the enormous potential of ADC payloads. With these expanded resources, Myricx is poised to fully leverage its NMTi-ADC platform, advancing both its own pipeline and strategic partnerships.”
-Maina Bhaman, Partner at Sofinnova Partners
How we partner with investors
We're keen to connect with seed and series A-focused funds to create and grow new companies offering unique early-stage investment opportunities.
Our Seed Fund investments are catalytic, with Cancer Research Horizons considered a validating investor by like-minded early-stage investors. An important impact measure for the fund is to leverage third-party capital alongside our own investments.
Are you a mentor who can help build start-up businesses?
We're looking for mentors and partners to join our network of world-leading technical experts, commercial and specialist advisors and seasoned entrepreneurs.
Share your expertise and help researchers:
- Understand licensing and intellectual property protection
- Develop strong commercial propositions
- Navigate company formation, management team building and scaling up capabilities
Interested in investing in world-leading cancer research?
We're seeking investors and co-investors across our portfolio.